comparemela.com

Latest Breaking News On - Comparing ponatinib - Page 1 : comparemela.com

Data from Across Incyte s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held. | May 25, 2023

United kingdomUnited statesTafasitamab monjuviPonatinib iclusigSteven steinMacrogenics incAmerican society of clinical oncologyInternational bloodMarrow transplant researchTakeda pharmaceuticals internationalLymphoma biology translational researchTakeda pharmaceutical companyDrug administrationEuropean unionIncyte corporationMillennium pharmaceuticals inc

Data from Across Incyte s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

United kingdomUnited statesTafasitamab monjuviGewinn nurCatalina lovemanPonatinib iclusigSteven steinGreg shertzerEuropean hematology associationLymphoma biology translational researchXencor incMacrogenics incMarrow transplant researchEuropean unionMillennium pharmaceuticals incIncyte corporation

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Elias jabbourFirst reportComparing ponatinibNewly diagnosedAcute lymphocytic leukemiaCall cancerAll leukemiaPh positiveOph allTyrosine kinase inhibitorsTki therapyCombination therapyBcr ablPonatinib dosePonatinib dosingComplete response

vimarsana © 2020. All Rights Reserved.